Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
|Poll|June 23, 2021
Poll: Medical Aid in Dying
Author(s)Psychiatric Times Editors
What are your thoughts on medical aid in dying?
Advertisement
Canada just passed a law that has opened a path to euthanasia for patients with psychiatric illness who find their conditions unbearable. In your opinion:
Should psychiatrists assist with medical aid in dying in general?
Should medical aid in dying be available to patients with psychiatric disorders?
If you have more to say on this subject, write us at
Advertisement
Related to this article
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
FDA Shelves Fast-Track Drug Review Initiative
3
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
4
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
5